Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
Read Now: TheBodyPRO.com Covers AIDS 2014
   
Ask the Experts About

Choosing Your MedsChoosing Your Meds
           
Rollover images to visit our other forums!
Recent AnswersAsk a Question
  
  • Email Email
  • Glossary Glossary


PEP n more pep
Feb 19, 2012

My pep meds were amended to be:

1) Aluvia 100/400 - every 12 hours 2) Combid 300 - every 12 hours 3) Stocrin 600 once a day

Is keeping the Stocrin included going to just help the success chances even more? Or is it totally unnecessary and should drop it. Doctor left it up to me but I don't know enough about these to make such decisions.

Lastly, if I were able to get my hands on Fuzeon, would taking it too be okay?

Thanks

Response from Dr. Young

Hi and thanks for posting.

Current US guidelines for PEP recommend the use of AZT/3TC (Combivir) and lopinavir/ritonavir (Kaletra/Alluvia) for 1 month. Efavirenz (Sustiva, Stocrin) is not recommended, nor is it helpful to add with Combivir and Aluvia. Same is true for enfuvirtide (Fuzeon) I'd stop the Stocrin.

Good luck!

BY



Previous
High Creatine on Atripla
Next
Switching from Atripla

  
  • Email Email
  • Glossary Glossary

 Get Email Notifications When This Forum Updates or Subscribe With RSS


 
Advertisement



Q&A TERMS OF USE

This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither TheBody.com nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint

Advertisement